Edwards Lifesciences (EW)

• Market cap: $44.1B
• 1 day: 1.19%
• 5 days: 0.92%
• 1 month: 7.58%
• 3 months: 11.94%
• 6 months: -15.79%
• Year to date: -1.01%
• 1 year: 0.93%
• 5 years: -5.06%
• 10 years: 238.81%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Employees: 19,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

147% more call options, than puts

Call options by funds: $733M | Put options by funds: $296M

4.13% less ownership

Funds ownership: 82.79% [Q2] → 78.65% (-4.13%) [Q3]

9% less funds holding

Funds holding: 1,280 [Q2] → 1,170 (-110) [Q3]

27% less repeat investments, than reductions

Existing positions increased: 359 | Existing positions reduced: 493

32% less capital invested

Capital invested by funds: $46B [Q2] → $31.3B (-$14.7B) [Q3]

44% less first-time investments, than exits

New positions opened: 139 | Existing positions closed: 249

57% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 6 (-8) [Q3]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $68 9% downside
• Avg. target: $78 4% upside
• High target: $90 20% upside

13 analyst ratings

• positive: 5 38%
• neutral: 8 62%
• negative: 0 0%

B of A Securities Travis Steed 0% 1-year accuracy 0 / 5 met price target	20% upside $90	Buy Upgraded	16 Dec 2024
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target	11% upside $83	Buy Maintained	11 Dec 2024
Goldman Sachs David Roman 54% 1-year accuracy 7 / 13 met price target	20% upside $90	Buy Maintained	5 Dec 2024
Truist Securities Richard Newitter 80% 1-year accuracy 40 / 50 met price target	4% upside $78	Hold Reiterated	5 Dec 2024
Stifel Rick Wise 62% 1-year accuracy 18 / 29 met price target	0% upside $75	Hold Maintained	5 Dec 2024